|
Aortic Aneurysm, Abdominal
|
0.400 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein E-deficient male and female mice (aged 7 wk; n = 25 per group) were infused with angiotensin II (AngII; 2000 ng/kg/min) plus β-aminopropionitrile (BAPN) in the drinking water for 28 d to test the effects of gender on AAA rupture.
|
31699539 |
2020 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiotensin-(1-7) Mitigated Angiotensin II-induced Abdominal Aortic Aneurysms in Apolipoprotein E Knockout Mice.
|
31658493 |
2020 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to define the role of MasR deficiency in AngII-induced atherosclerosis and AAA formation and severity in hypercholesterolemic male mice.
|
30850299 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
Biomarker
|
disease |
BEFREE |
Ninety percent of angiotensin II-infused mice developed AAA, with 50% mortality because of aneurysm rupture.
|
31147569 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role of Non-POU-domain-containing octamer-binding protein (NONO) in the formation and development of angiotensin II (Ang II)-induced abdominal aortic aneurysm (AAA) in apolipoprotein E-knockout (ApoE<sup>-/-</sup> ) mice is still unknown.
|
31512366 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiotensin II (Ang-II) was used to construct the AAA model in <i>ApoE</i><sup>-<i>/</i>-</sup> mice.
|
31467666 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
After infusion of angiotensin II (Ang II) for 4 weeks and β-aminopropionitrile (BAPN) for 2 weeks, 58% of C57/6J wild-type (WT) mice developed AAA associated with enhanced expression of IL-18; however, disease incidence was significantly lower in IL-18<sup>-/-</sup> mice than in WT mice (p < 0.01), although no significant difference was found in systolic blood pressure between WT mice and IL-18<sup>-/-</sup> mice in this model.
|
31445353 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
Biomarker
|
disease |
BEFREE |
Compared to the abdominal aortic aneurysm modeling method in rabbits based on pancreatic elastase alone, the abdominal aortic aneurysm modeling method in rabbits using pancreatic elastase combined with angiotensin II maintained the morphology of the abdominal aortic aneurysm for a longer time, showing an important application value for the long-term observation of changes in abdominal aortic aneurysms.
|
30373483 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
Biomarker
|
disease |
BEFREE |
AAA in male C57BL/6 J mice was induced by coadministration of angiotensin II (Ang II) and 3,4-benzopyrene (BaP).
|
30614051 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
Biomarker
|
disease |
BEFREE |
One amino acid change of Angiotensin II diminishes its effects on abdominal aortic aneurysm.
|
30944205 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
Biomarker
|
disease |
BEFREE |
The findings of the present study indicated that Gambogic acid prevents angiotensin II‑induced AAA through inflammatory and oxidative stress‑dependent targeting of the PI3K/Akt/mTOR and NF‑κB signaling pathways.
|
30535428 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, we found that the CXCR2 expressions in AAA tissues from human and angiotensin II (Ang II)-infused apolipoprotein E knockout (Apo E<sup>-/-</sup>) mice were significantly increased.
|
30535755 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
Biomarker
|
disease |
BEFREE |
The angiotensin II (Ang II)-induced AAA model in ApoE-/- mice and the CaCl<sub>2</sub>-induced AAA model in wild-type C57BL/6 mice were used.
|
31534503 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
Biomarker
|
disease |
BEFREE |
To determine the effects of GBE in mice with established AAAs, male apoE-/- mice were firstly infused with AngII for 28 days to develop AAAs, and then administered either GBE or vehicle in mice with established AAAs, which were continuously infused with AngII for another 56 days.
|
29777203 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Daily intraperitoneal injection of GSK'074 at 0.93 mg/kg significantly attenuated aortic expansion in two mouse models of AAA (calcium phosphate: DMSO 66.06 ± 9.17% vs GSK'074 27.36 ± 8.25%, P < 0.05; Angiotensin II: DMSO 85.39 ± 15.76% vs GSK'074 36.28 ± 5.76%, P < 0.05).
|
30842407 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
Biomarker
|
disease |
BEFREE |
We evaluated the in vitro properties of montelukast and its in vivo activities in an angiotensin II-infused apolipoprotein E-deficient (apoE<sup>-/-</sup>) AAA mouse model.
|
31263710 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
Biomarker
|
disease |
BEFREE |
Niacin markedly reduced AAA formation in both AngII and CaCl2 models, diminishing adventitial immune cell infiltration, concomitant inflammatory responses, and matrix degradation.
|
31710686 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of Iars significantly reduced the incidence of angiotensin II (AngII)-induced AAA in mice, coincident with decreased activity of the p38 MAPK pathway and increased PI3K pathway activity.
|
30905780 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD11c+ depletion commencing after AAA establishment by 14 days of AngII infusion, was also shown to lead to smaller AAAs than controls after a further 14 days (D.tox, 1.54 ± 0.04 mm vs Vehicle control, 1.80 ± 0.03 mm, P<0.001).
|
31696215 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
Biomarker
|
disease |
BEFREE |
Osmotic minipumps with a continuous infusion of Ang II (angiotensin II; 1000 ng/[kg·min]) to induce AAAs were implanted in apolipoprotein-deficient mice (N=58).Animals were assigned to 2 groups.
|
30871334 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
Biomarker
|
disease |
BEFREE |
Employing an angiotensin II (AngII)-stimulated apolipoprotein E knockout (apoE -/-) mice fed a standard, non-atherogenic diet, Rb deficiency increased aortic diameter, stimulated abdominal aortic aneurysm (AAA) development, and reduced survival.
|
31214845 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
Biomarker
|
disease |
BEFREE |
The preventive effects of CAG on AAA were verified in another AAA mouse model induced by angiotensin II in ApoE<sup>-/-</sup> mouse.
|
30302749 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
Biomarker
|
disease |
BEFREE |
Caloric Restriction Exacerbates Angiotensin II-Induced Abdominal Aortic Aneurysm in the Absence of p53.
|
30686087 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
Biomarker
|
disease |
BEFREE |
Loss of APLN potentiated angiotensin II (Ang II)-induced AAA formation, aortic rupture, and reduced survival.
|
31189595 |
2019 |
|
Aortic Aneurysm, Abdominal
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiotensin II infusion into these animals resulted in substantially exaggerated elevation in blood pressure and development of AAA, which was accompanied by excessive eNOS uncoupling activity (featured by significantly impaired tetrahydrobiopterin and nitric oxide bioavailability), vascular remodeling (MMP2 activation, medial elastin breakdown and adventitial fibrosis) and inflammation (macrophage infiltration).
|
30954686 |
2019 |